Free shipping starts now, no minimum, no coupons required!


Olmesartan Acid, Votum
An Antagonist of Angiotensin II Receptor Type-1
Cat #: O-125
Alternative Name Olmesartan Acid, Votum
Lyophilized Powder yes
  • Bioassay Tested
  • Source Synthetic
    MW: 446.5
    Purity: ≥99%
    Effective concentration 1 nM – 1 µM.
    Chemical name 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.
    Molecular formula C24H26N6O3.
    CAS No.: 144689-24-7.
    PubChem CID 158781
    Activity Olmesartan is an Angiotensin II Type 1 Receptor Antagonist1.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
    Solubility 20 mM in DMSO. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Up to four weeks at 4°C or three months at -20°C.
    Our bioassay
    • Alomone Labs Olmesartan inhibits the activation of Angiotensin AT1R expressed in CHO-K1-mt Aequorin-Gα16 cells.
      Alomone Labs Olmesartan inhibits the activation of Angiotensin AT1R expressed in CHO-K1-mt Aequorin-Gα16 cells.
      Dose response curve for the inhibition of AT1R expressed in CHO-K1-mt Aequorin-Gα16 cells. Ca2+ response, as detected by elevation in aequorin derived fluorescence following 0.04 nM Angiotensin II application, was inhibited by increasing concentrations of Olmesartan (#O-125). 1 µM Olmesartan fully inhibited the activation by Angiotensin II.
    References - Scientific background
    1. Kurtz, T.W. et al. (2012) Vasc. Health Risk Manag. 8, 133.
    2. Neutel, J.M. (2001) Am. J. Cardiol. 87, 37C.
    Scientific background

    Angiotensin II is responsible for vasoconstriction in the renin-angiotensin system. In addition to its direct effect on blood vessels, it stimulates the synthesis and release of aldosterone and also promotes renal tubular reabsorption of sodium, resulting in water retention1.

    Olmesartan (also known as CS-866) is a synthetic antagonist of the Angiotensin II type 1 receptor. It has an effective concentration of 1 nM – 1 μM and an IC50 of 7.7 nM for bovine adrenal cortical membranes. After administration, Olmesartan is rapidly de-esterified within the gastrointestinal tract to form RNH-6270, a competitive Angiotensin receptor antagonist with high affinity for the receptor. The P-450 enzyme system is not involved in the conversion of CS-866 to its active metabolite. It has been shown that Olmesartan’s pharmacokinetics is suitable for administration once a day. The half-life of the drug is approximately 13 hours which places Olmesartan in the mid-range in terms of half-life compared with other Angiotensin antagonists. Olmesartan induces a beneficial anti-hypertensive effect about two weeks after the beginning of therapy. It is effective in patients of all age groups causing a mean blood pressure reduction of 12 mm Hg in DBP and 15 mm Hg in SBP when administered at a dosage of 20 mg2.

    Target AT1R angiotensin receptors
    Last update: 22/09/2020

    Olmesartan (#O-125) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Shipping and Ordering information